Overview

• Researchers used a novel [68Ga]Ga-NOTA-insulin radiotracer and PET scans to demonstrate delivery to 11 key memory and cognition regions
• Subjects with mild cognitive impairment exhibited rapid initial uptake and quicker clearance compared with cognitively normal participants
• Elevated ptau217 levels in women were associated with reduced insulin absorption across several brain regions, suggesting amyloid pathology influences delivery
• The six-spray nasal system proved safe and tolerable, with only two participants reporting mild headaches that resolved within 24 hours
• Wake Forest University and Aptar Pharma will conduct larger 12–18 month trials to assess how vascular health, amyloid burden and sex differences affect brain insulin uptake